NCT03798743View on ClinicalTrials.gov

Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

December 30, 2021

Study Completion Date

March 1, 2022

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Sintilimab Combined With Docetaxel

Sintilimab 200mgi.v q3w Docetaxel 75mg/m2 i.v q3w

Trial Locations (1)

410013

Hunan Provincal Tumor Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER

NCT03798743 - Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study | Biotech Hunter | Biotech Hunter